CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, today announced it has completed a USD $75 million financing round (circa £57 million). The fundraise was led by Elevage Medical Technologies, backed by Patient Square Capital, and joined by British Patient Capital, the largest domestic investor in UK venture and venture growth opportunities, Cambridge Innovation Capital, Jonathan Milner, GK Goh, M&G Catalyst, E Ink Holdings, Michael D.

英国剑桥和波士顿--（商业新闻短讯）--生物技术公司Nuclera通过其台式蛋白质系统加速蛋白质表达和纯化工作流程，今天宣布已完成7500万美元的融资回合（约5700万英镑）。此次募资由Elevage Medical Technologies牵头，Patient Square Capital支持，英国Patient Capital是英国风险投资和风险增长机会的最大国内投资者，剑桥创新资本、乔纳森·米尔纳、GK Goh、M＆G Catalyst、E Ink Holdings、迈克尔·D。

McCreary, Uni Power Group, and Verve Ventures. Taylor Wessing advised Nuclera on the transaction. The investment will enable the continued commercialization of Nuclera’s eProtein Discovery™ benchtop system, particularly in the US and across Europe..

McCreary、Uni Power Group和Verve Ventures。泰勒·维辛（TaylorWessing）为Nuclera提供交易顾问。这项投资将使Nuclera的eProtein Discovery™台式系统继续商业化，特别是在美国和整个欧洲。。

Nuclera’s eProtein Discovery system is designed to speed up protein expression and purification in research labs, including those using AI for protein design. The system reduces the time and cost of these processes by automating construct screening, allowing for protein scale-up, and producing milligram amounts of protein in less than 48 hours, compared to the months or years other methods can take.

Nuclera的eProtein Discovery系统旨在加速研究实验室中的蛋白质表达和纯化，包括那些使用AI进行蛋白质设计的实验室。该系统通过自动化构建体筛选，允许蛋白质放大，并在不到48小时内产生毫克量的蛋白质，与其他方法可能需要的数月或数年相比，减少了这些过程的时间和成本。

Using digital microfluidics, protein quality assays, and cell-free protein synthesis on eProtein Discovery cartridges, eProtein Discovery provides rapid access to high-quality proteins at scale, whether using cell-free or cell-based methods..

使用数字微流体技术，蛋白质质量测定和eProtein Discovery墨盒上的无细胞蛋白质合成，eProtein Discovery提供了大规模快速获取高质量蛋白质的方法，无论是使用无细胞方法还是基于细胞的方法。。

The eProtein Discovery system has already been installed at contract research organizations (CROs), biotech and biopharma companies, as well as at leading academic institutes, including University College London, University of Cambridge, University of Southampton, University of Manchester, The Flanders Institute for Biotechnology (VIB) in Belgium, and the CRUK Cambridge Institute..

eProtein Discovery系统已安装在合同研究组织（CRO），生物技术和生物制药公司以及领先的学术机构，包括伦敦大学学院，剑桥大学，南安普顿大学，曼彻斯特大学，比利时弗兰德斯生物技术研究所（VIB）和克鲁克剑桥研究所。。

Dr Michael Chen, CEO and co-founder, Nuclera, said: “This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made. This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world.

Nuclera首席执行官兼联合创始人迈克尔·陈博士（MichaelChen）表示：“这项重大投资表明，我们对我们的团队、我们的eProtein发现系统以及我们彻底改变蛋白质制造方式的潜力充满信心。这笔资金将加速我们的使命，提供现成的台式蛋白质筛选和制造工具，以增强全世界蛋白质科学家的能力。

We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come.”.

我们很高兴能够加强对客户的支持，使他们能够在未来的许多年中更有效地生产用于药物发现的蛋白质。”。

Dr Michael Wasserman, Chief Operating Officer, Elevage Medical Technologies, commented: “Nuclera has developed a solution for one of the leading obstacles in drug discovery: access to proteins that are needed throughout the drug discovery process. The demand for Nuclera’s technology is expanding rapidly, as AI and structural biology continues to drive the pace of new discoveries in life sciences and drug development.

。

Elevage is proud to support Nuclera and its leadership team as it continues to bring the eProtein Discovery System to drug discovery researchers across the globe to address their need for bespoke, rapid and convenient delivery of quality proteins.”.

Elevage很自豪地支持Nuclera及其领导团队，因为它继续将eProtein Discovery系统带给全球的药物发现研究人员，以满足他们对定制，快速和方便递送优质蛋白质的需求。”。

Dr Jonathan Milner, Chairman of the Nuclera Board of Directors, founder and former CEO of Abcam, Inc and CEO of Meltwind Advisory, added: “The ability to screen multiple protein expression profiles and print purified proteins in as little as 24 hours will revolutionize laboratory workflows and make a demonstrable impact in research and drug discovery timelines.

Nuclera董事会主席、Abcam公司创始人兼前首席执行官兼Meltwind Advisory首席执行官乔纳森·米尔纳博士补充说：“在24小时内筛选多种蛋白质表达谱并打印纯化蛋白质的能力将彻底改变实验室工作流程，并对研究和药物发现时间表产生明显影响。

Aligning with Nuclera more closely following my appointment as Chairman of the Board, I am excited as the Company’s pioneering solution continues to be recognized by the industry and demonstrated through this funding round.”.

在我被任命为董事会主席后，我更紧密地与Nuclera保持一致，我很兴奋，因为该公司的开创性解决方案继续得到业界的认可，并通过这轮融资得到证明。”。

For more information about Nuclera’s eProtein Discovery system, please visit: https://www.nuclera.com/system/

有关Nuclera的eProtein Discovery系统的更多信息，请访问：https://www.nuclera.com/system/